Product hopping in the drug industry — lessons from Albuterol

Wouters, O. J.ORCID logo, Feldman, W. B. & Tu, S. S. (2022). Product hopping in the drug industry — lessons from Albuterol. New England Journal of Medicine, 387(13), 1153 - 1156. https://doi.org/10.1056/NEJMp2208613
Copy

Product hops to albuterol inhalers containing hydrofluoroalkane rather than chlorofluorocarbons cost payers and patients billions of dollars. Without patent and regulatory reform, this pattern is likely to be repeated.
Item Type Article
Copyright holders © 2022 Massachusetts Medical Society.
Departments LSE > Academic Departments > Health Policy
DOI 10.1056/NEJMp2208613
Date Deposited 14 Oct 2022
Acceptance Date 01 Sep 2022
URI https://researchonline.lse.ac.uk/id/eprint/116986

Explore Further

picture_as_pdf
subject
Accepted Version
Creative Commons: Attribution-No Derivative Works 4.0
Creative Commons: Attribution-No Derivative Works 4.0
Download

Export as

EndNote BibTeX Reference Manager Refer Atom Dublin Core JSON Multiline CSV
Export

Downloads
View more statistics